Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001251 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Intrathecal Mafosfamide
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00001251: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001251 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001251, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to determine efficacy of intrathecal mafosfamide, a preactivated derivative of cyclophosphamide against meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy). The maximally tolerated dose for intrathecal mafosfamide will be established in a limited dosage escalation schedule. The CSF pharmacokinetics of intrathecal mafosfamide will also be studied. Mafosfamide will be administered intrathecally on a bi-weekly basis for four weeks, followed by twice monthly administration for four months and then monthly IT administration. A minimum of 9 patients will be studied in each disease category (leukemias, lymphomas, and other malignancies refractory to conventional therapy).
Interventions
- DRUG Mafosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 1989-11 |
| Est. Completion | 2003-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001251
The ClinicalTrials.gov registry entry for NCT00001251 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mafosfamide is the first listed.
NCT00001251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001251 about?
NCT00001251 is a clinical study titled "Phase I Study of Intrathecal Mafosfamide". The purpose of this study is to determine efficacy of intrathecal mafosfamide, a preactivated derivative of cyclophosphamide against meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy). The maximally tolerated dose for intrathecal mafosfamide will be establ...
What is the current status of trial NCT00001251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 1989-11. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00001251?
The interventions under investigation include: Mafosfamide (DRUG).
Who is sponsoring clinical trial NCT00001251?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.